Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NZ09
UPID:
UBAP1_HUMAN
Alternative names:
Nasopharyngeal carcinoma-associated gene 20 protein
Alternative UPACC:
Q9NZ09; B7Z348; B7Z8N9; D3DRL7; F5GXE2; F5H0J8; Q4V759; Q53FP7; Q5T7B3; Q6FI75; Q8NC52; Q8NCG6; Q8NCH9
Background:
Ubiquitin-associated protein 1, also known as Nasopharyngeal carcinoma-associated gene 20 protein, plays a crucial role in the ESCRT-I complex, regulating vesicular trafficking processes. It binds to ubiquitinated cargo proteins, facilitating their sorting into multivesicular bodies (MVBs) and is instrumental in the proteasomal degradation of ubiquitinated cell-surface proteins, including EGFR and BST2.
Therapeutic significance:
The protein's involvement in Spastic paraplegia 80, an autosomal dominant neurodegenerative disorder, underscores its therapeutic significance. Understanding the role of Ubiquitin-associated protein 1 could open doors to potential therapeutic strategies for managing and treating this condition.